1.
J Soc Pediatr Nurs
; 1(1): 43-5, 1996.
Artigo
em Inglês
| MEDLINE
| ID: mdl-8951150
Assuntos
Reforma dos Serviços de Saúde/legislação & jurisprudência , Medicaid/legislação & jurisprudência , Síndrome da Imunodeficiência Adquirida/economia , Financiamento Governamental , Reforma dos Serviços de Saúde/economia , Humanos , Medicaid/economia , Serviços de Saúde Escolar/economia , Estados Unidos
2.
J Perinat Neonatal Nurs
; 7(4): 65-78, 1994 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-8151512
RESUMO
Gene therapy is an innovative technique utilized in the treatment of a primary immunodeficiency known as severe combined immune deficiency syndrome (SCIDS). The first human trials of gene therapy for SCIDS were conducted in 1990, by attempting to insert the gene for adenosine deaminase into peripheral white blood cells to treat children with adenosine deaminase (ADA)-deficiency SCIDS. Recently, three infants with ADA-deficiency SCIDS received gene therapy with genetically manipulated hematopoietic stem cells. This clinical update reviews basic immunology function and malfunction, describes gene therapy, and specifically highlights hematopoietic stem cell gene therapy treatment for ADA-deficiency SCIDS.